Guardant Health Inc - Company Profile
Powered by 
All the data and insights you need on Guardant Health Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Guardant Health Inc Strategy Report
- Understand Guardant Health Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and also recurrence monitoring. The company test platform includes GuardantOMNI, GuardantINFINITY and GuardantINFORM. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Pao Alto, California, the US.
Headquarters
United States of America
Address
3100 Hanover Street, Palo Alto, California, 94304
Website
guardanthealth.com
Telephone
1 650 2907575
No of Employees
1,779
Industry
Medical Equipment
Ticker Symbol & Exchange
GH (NASD)
Revenue (2022)
$563.9M
25.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
26.8%
(2022 vs 2021)
Market Cap*
$2.0B
Net Profit Margin (2022)
XYZ
41.6%
(2022 vs 2021)
* As of and is in US$
Guardant Health Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Guardant360 | Cancer Screening and Test | Guardant360 |
| GuardantOMNI | Blood Test | |
| Guardant Reveal | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company and Cancer Research Horizons entered into a partnership to advance the development and precision of cancer detection and treatment. |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with Illumina Inc to resolve their pending litigation. |
| 2023 | Contracts/Agreements | In February, the company and Sampled initiated a project for a large-scale lung cancer screening study. |
Competitor Comparison
| Key Parameters | Guardant Health Inc | Thermo Fisher Scientific Inc | Illumina Inc | Qiagen NV | Natera Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Netherlands | United States of America |
| City | Palo Alto | Waltham | San Diego | Venlo | Austin |
| State/Province | California | Massachusetts | California | - | Texas |
| No. of Employees | 1,779 | 122,000 | 10,590 | 5,967 | 3,282 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Helmy Eltoukhy | Chief Executive Officer; Director | Executive Board | 2013 | 44 |
| AmirAli Talasaz | Director; Co- Chief Executive Officer | Executive Board | 2013 | 43 |
| Michael Bell | Chief Financial Officer | Senior Management | 2021 | 54 |
| Michael Wiley | Chief Financial Officer | Senior Management | 2021 | 54 |
| Kumud Kalia | Chief Information Officer - Oncology; Chief Information Officer | Senior Management | 2020 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward